Effects of sustained and intermittent paclitaxel therapy on tumor repopulation in ovarian cancer

Molecular Cancer Therapeutics

Volumn 7, Issue 3, 2008, Pages 630-637

  Vassileva, Vessela ^a   Allen, Christine J ^a   Piquette Miller, Micheline ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BROXURIDINE; CASPASE 3; PACLITAXEL;

ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ATTENUATION; CANCER MODEL; CANCER SURVIVAL; CELL GROWTH; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; CLONOGENESIS; CONTROLLED STUDY; DRUG INTERMITTENT THERAPY; DRUG UPTAKE; FEMALE; HUMAN; HUMAN CELL; IMMUNOASSAY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NICK END LABELING; NONHUMAN; OVARY CANCER; POPULATION; PRIORITY JOURNAL; THERAPY EFFECT; TREATMENT RESPONSE; TUMOR CELL; TUMOR GROWTH; XENOGRAFT;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL DIVISION; CELL LINE, TUMOR; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; OVARIAN NEOPLASMS; PACLITAXEL;

EID: 41649097550     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-07-2117     Document Type: Article

References (27)

1. Bookman MA, Ozols RF. Factoring outcomes in ovarian cancer. J Clin Oncol 1996;14:325-7.
2. Trimble E. Concluding remarks: optimal treatment for women with ovarian cancer. Semin Oncol 2006;33:25-6.
3. duBois A, Neijit J, Thigpen J. First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer - a new standard of care? Ann Oncol 1999;10:35-41.
4. McGuire W, Hoskins W, Brady M et al. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). Semin Oncol 1996;23:40-7.
5. Dische S, Saunders, M, Barrett A, Harvey A, Gibson D, Parmar M. A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol 1997;44:123-36.
6. Kim J, Tannock I. Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat Rev Cancer 2005;5:516-25.
7. Davis A, Tannock I. Repopulation of tumour cells between cycles of chemotherapy: a neglected factor. Lancet Oncol 2000;1:86-93.
8. Vassileva V, Grant J, De Souza R, Allen C, Piquette-Miller M. Novel biocompatible intraperitoneal drug delivery system increases tolerability and therapeutic efficacy of paclitaxel in a human ovarian cancer xenograft model. Cancer Chemother Pharmacol 2007;60:07-14.
9. Micha J, Goldstein B, Birk C, Rettenmaier MA, Brown JVR. Abraxane in the treatment of ovarian cancer: the absence of hypersensitivity reactions. Gynecol Oncol 2006;100:437-8.
10. Mesiano S. Ferrara N, Jaffe RB. Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol 1998;153:1249-56.
11. Jung H, Kruger H, Brammer I, Zywietz F, Beck-Bornholdt H. Cell population kinetics of the rhabdomyosarcoma R1H of the rat after single doses of X-rays. Int J Radiat Biol 1990;57:567-89.
12. Malaise E, Tubiana M. Growth of the cells of an experimental irradiated fibrosarcoma in the C3H mouse. C R Acad Sci Hebd Seances Acad Sci D 1966;263:292-5.
13. Szczepanski L, Trott KR. Post-irradiation proliferation kinetics of a serially transplanted murine adenocarcinoma. Br J Radiol 1975;48:200-8.
14. Baltali E, Altundag K, Ozisik Y, Guler N, Tekuzman G. Weekly paclitaxel in pretreated metastatic breast cancer: retrospective analysis of 52 patients. Tohoku J Exp Med 2004;203:205-10.
15. Repetto L, Comandini D, Mammoliti S, Pietropaolo M, Del Mastro L. Weekly paclitaxel in elderly patients with advanced breast cancer: a dose-finding study. Drugs R D 2004;5:11-5.
16. Wist E, Sommer H, Ostenstad B, Risberg T, Fjaestad K. Weekly one-hour paclitaxel as first-line chemotherapy for metastatic breast cancer. Acta Oncol 2004;43:11-4.
17. De Feudis P, Vignati S, Rossi C, et al. Driving p53 response to Bax activation greatly enhances sensitivity to Taxol by inducing massive apoptosis. Neoplasia 2000;2:202-7.
18. Hawkins D, Demers G, Galloway D. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 1996;56:892-8.
19. Rowinsky E, Donehower R, Jones R, Tucker R. Microtubule changes and cytotoxicity in leukemic cell lines treated with Taxol. Cancer Res 1988;48:4093-100.
20. Lopes N, Adams E, Pitts T, Bhuyan B. Cell kill kinetics and cell cycle effects of Taxol on human and hamster ovarian cell lines. Cancer Chemother Pharmacol 1993;32:235-42.
21. Tishler R, Geard C, Hall E, Schiff P. Taxol sensitizes human astrocytoma cells to radiation. Cancer Res 1992;52:3495-7.
22. Tishler R, Schiff P, Geard C, Hall E. Taxol: a novel radiation sensitizer. Int J Radiat Oncol Biol Phys 1992;22:613-7.
23. Kelland L, Abel G. Comparative in vitro cytotoxicity of Taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. Cancer Chemother Pharmacol 1992;30:444-50.
24. Milas L, Hunter NR, Kurdoglu B, et al. Kinetics of mitotic arrest and apoptosis in murine mammary and ovarian tumors treated with Taxol. Cancer Chemother Pharmacol 1995;35:297-303.
25. Au J, Kumar R, Li D, Wientjes M. Kinetics of hallmark biochemical changes in paclitaxel-induced apoptosis. AAPS Pharm Sci 1999;1:E8.
26. Au J, Li D, Gan Y, et al. Pharmacodynamics of immediate and delayed effects of paclitaxel: role of slow apoptosis and intracellular drug retention. Cancer Res 1998;58:2141-8.
27. Kuh H, Jang S, Wientjes M, Weaver J, Au J. Determinants of paclitaxel penetration and accumulation in human solid tumor. J Pharmacol Exp Ther 1999;290:871-80.